| CASE REPORT |
|
| Ahead of Print |
|
|
Successful treatment with durvalumab: A case report and review
Ana Peláez Bejarano, Olalla Montero Pérez
Hospital Pharmacy, Unidad de Gestión Clínica Farmacia, Hospital Juan Ramón Jiménez, Huelva, Spain
Correspondence Address:
Ana Peláez Bejarano,
Unidad de Gestión Clínica Farmacia, Hospital Juan Ramón Jiménez, Ronda Norte S/N, 21005 Huelva
Spain
 Source of Support: None, Conflict of Interest: None DOI: 10.4103/jcrt.jcrt_1430_21
|
|
|
Stage III non-small-cell lung cancer (NSCLC) represents a heterogeneous group of disease entities with multimodality treatments. For most patients, platinum-based doublet with concurrent chemoradiotherapy (CRT) has become the first-choice treatment over the past decade. Immune checkpoint inhibition has revolutionized the management of metastatic NSCLC; however, no major advances in systemic therapy for Stage III NSCLC have been made. The following report is the case of a patient with unresectable Stage IIIA NSCLC successfully treated with durvalumab. The patient completed 1 year of treatment without interruptions, and disease control has been maintained for more than 20 months since the start of durvalumab.
|
|
|
|
|
|
|
Search Pubmed for